Background: Leptin may play a role in mediating obesity-related hypertension. However, its effects on the vasculature and blood pressure (BP) remain poorly defined in humans.
INTRODUCTION H
YPERLEPTINEMIA MAY BE A MECHANISM linking obesity with hypertension. 1, 2 Leptin is secreted by adipocytes and modulates sympathetic nervous system activity to regulate body weight. Therefore, a potential consequence of hyperleptinemia may be elevated arterial blood pressure (BP). These autonomic actions are countered by direct leptin-mediated vasodilatation. 3 "Selective tissue resistance" to leptin may promote chronic hypertension in human obesity if its pressor actions remain sensitive while the vasodilatory responses are blunted. 2, 4 Indeed, several animal experiments have demonstrated that leptin sub-acutely causes a net increase in BP. 4, 5 Leptin's hemodynamic actions remain incompletely described in humans, therefore the aim of this study was to investigate the direct effect of leptin on BP and vascular function in healthy adults.
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METHODS
Two separate experiments following use of recombinant methionyl human leptin (rmetHuLeptin) (Amgen Inc, Thousand Oaks, CA) were performed. The acute study was prospectively performed at the University of Michigan and approved by its Institutional Review Board. Fifteen healthy nonsmoking adults with a body mass index (BMI) Ͻ 27 kg · m Ϫ2 and without cardiovascular risk factors signed informed consent and were enrolled. None of the participants were taking any medication known to alter BP or endothelial function. Subjects entered into a randomized, double-blind, cross-over study (2 week washout) of r-metHuLeptin 0.2 mg · kg Ϫ1 SC versus placebo (sorbitol and sodium acetate, pH 4.0, of the same volume). Subjects fasted more than 8 hours overnight, had brachial artery flow mediated dilatation (FMD) performed, 6 and had blood drawn before and 2 and 4 hours after injections. Three seated BP values in the dominant arm were measured (Omron 711AC, Omron Healthcare, Inc., Bannockburn, IL). and averaged at the start and at the 4 hour time point.
As far as we are aware, there have been no published data on the long-term effects of leptin on BP in humans. In order to complement the results of the acute study findings, to gain insight into the more biologically important long-term actions of leptin, we obtained permission from the investigative team (A.M.D., Amgen Inc, Thousand Oaks, CA) to analyze the BP results (which had not been published) from a previously performed weight loss study. This chronic study was conducted in obese subjects from September 1997 to August 1998 at 8 clinics in the Netherlands, Sweden, and the United Kingdom. Subjects were otherwise healthy adults, with the exception of obesity. Those with comorbidities such as drugtreated diabetes, hyperlipidemia, and uncontrolled hypertension were excluded. All subjects provided written informed consent, and an independent Ethics Committee at each study site approved the protocol. Subjects were randomly assigned in a 1:1:1 allocation to 3 different treatment regimens of r-metHuLeptin or matching placebo allocated 3:1 (active drug:placebo) within each regimen (10 mg subcutaneously [SC] daily before noon [QAM], or 10 mg SC daily after noon [QPM], or 10 mg SC twice a day [BID] ). Obese subjects with a BMI between 27.5 and 37.0 kg · m Ϫ2 were enrolled in a 3-week dietary lead-in phase in which subjects were prescribed a 2100 kJ · day Ϫ1 (500 kcal · day Ϫ2 ) deficit diet. All subjects received single-blinded placebo injections throughout the dietary lead-in phase. Only subjects with a weight loss between 0 and 5.0 kg and a BMI over 25.0 kg · m Ϫ2 were eligible to continue into the treatment phase. Subjects were then randomized into the 3 treatment regimens in a stratified fashion according to body weight loss during the dietary lead-in (Ͻ2.0 kg or Ն2.0 kg). Drug or placebo was self administered SC during the study. Fasting BP was measured in the morning (7-9 am) at the start and end of the treatment phase by standardized methods across sites. Subjects rested in a sitting position for 5 minutes and a single BP was measured by ausculatation using appropriate-sized arm cuffs and resting heart rate was determined. Blood was then drawn for fasting plasma leptin levels.
In our acute study, BP responses were compared by paired t-test. FMD values at the 0, 2, 
RESULTS
The characteristics of the patients in the acute study are shown in Table 1 . There were no significant changes in BP 4 hours after r-metHuLeptin injection compared to placebo (Table 2) . Data on 1 patient were lost and not included. Figure 1 demonstrates that brachial FMD was significantly enhanced by r-metHuLeptin after 2 hours and trended towards an increase at 4 hours. Mean plasma leptin concentrations increased from a normal baseline value of 9.0 Ϯ 6.8 to 135 Ϯ 39.3 ng · mL Ϫ1 2 hours after r-metHuLeptin injection. The increase in leptin (mean ϭ 126.4 ng · mL Ϫ1 ) correlated to the change in brachial FMD at 2 hours (rϭ0.52, Pϭ.059). Table 3 shows the baseline characteristics of the patients that were previously enrolled in the long-term weight loss study. There were no changes in basal brachial artery diameter after leptin. The reductions in weight, BP and heart rate did not differ significantly between groups (Table 4) . Baseline mean plasma leptin was the same for each group (19 Ϯ 14 ng · mL Ϫ1 ), however, levels at day 85 were higher in the r- 
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metHuLeptin (448 Ϯ 474 ng · mL Ϫ1 ) versus the placebo group (18 Ϯ 13 ng · mL Ϫ1 ).
DISCUSSION
Leptin may play a role in obesity-related hypertension and alter vascular function. 4, 5 Few data exist on the BP and vascular actions of leptin in humans to confirm this hypothesis. We have made one of the first attempts to address the relevance of this mechanistic pathway in humans by examining both the acute and chronic actions of exogenous leptin. Within hours, an increased plasma leptin level enhanced endothelial function (brachial FMD) in nonobese adults and did not alter BP. From the data that is available from a previously performed study, marked chronic hyperleptinemia also did not appear to affect BP or heart rate in obese adults.
It has been hypothesized that selective leptin resistance, in the presence of chronic hyperleptinemia due to obesity, could promote hypertension. 2 However, there is no direct evidence to support this hypothesis in humans. Cross-sectional studies linking BP, obesity, and leptin levels cannot discern physiologicallycausal roles from "innocent" associations. Intervention trials of exogenous leptin thus provide unique opportunities to directly address whether leptin per se plays a causal role in altering hemodynamics in humans. Our findings corroborate 2 prior experiments, which reported that leptin acutely enhances vasodilatory pathways in humans without altering BP over hours. 7, 8 Our current study is the first experiment to demonstrate that leptin enhances Values are mean Ϯ SD. Leptin group represents mean responses of all patients placed upon r-metHuLeptin at all doses.
P ϭ 2 samples t-test comparing day 85 changes between r-metHuLeptin and placebo groups n ϭ number of patients where measurement was made per group "endothelial function" as assessed by the standardized brachial FMD protocol. Moreover, the more relevant long-term hemodynamic actions of leptin have not been previously reported. In this analysis of the data from a previous chronic study, high dose r-metHuLeptin produced extreme hyperleptinemia, but did not significantly increase BP or heart rate compared to control patients with the same modest amount of weight loss. If high physiologic levels of leptin were contributing to elevated BP in humans, it would be expected that exogenous leptin would produce even further elevations in BP, or at the very least blunt the hypotensive effect of the observed weight loss. This lack of a prohypertensive action of pharmacologically-induced chronic extreme hyperleptinemia, coupled with the confirmation that leptin acutely enhances endothelial function without altering BP, does not support the hypothesis that leptin per se directly plays a causal role in elevating BP in humans. We recognize that our findings are the first attempt to specifically investigate both the acute and chronic effects of leptin on BP in humans. Therefore, there are several limitations in our studies that require these observations to be corroborated by future studies prior to making any definitive statement about the existence or nonexistence of a prohypertensive action of leptin. We cannot discount that the exogenous source of leptin and nonphysiologic plasma kinetics and marked plasma concentrations may not represent human (patho)physiology and may have contributed to our null findings. Since the weight loss in the leptin limb was not statistically greater than placebo, it is possible that the physiological actions of leptin were blunted in these patients (i.e., nonselective resistance). This may have contributed to a lack of a potential prohypertensive action. However, the particular advantages of these data are that they demonstrate that for equal degrees of weight loss, marked hyperleptinemia per se does not directly elevate BP. Finally, both studies were not specifically designed to detect small treatment differences in BP change. Larger studies using more sensitive techniques may uncover smaller effects missed in our studies (type 2 errors). However, even if a small effect were uncovered, it would not be consistent with leptin playing a major role in mediating obesity-related hypertension.
In summary, acute elevations in plasma leptin rapidly enhance conduit endothelial function as assessed by brachial FMD. We did not demonstrate that acute or chronic hyperleptinemia raises BP in healthy humans. More in-depth studies to confirm or refute a role for leptin in mediating obesity-hypertension in both lean and obese humans are clearly warranted based upon our initial findings.
